SCHEMBL13046763

SCHEMBL13046763

CCOC(=O)c1sc(-c2ccc(C(C)(F)F)cc2)nc1CBr

nearest known ligand 0.61

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.61
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
KDM4E B2RXH2 1/20 0.61
HSP90AA1 P07900 1/20 0.61
CRHBP P24387 1/20 0.61
CRHR2 Q13324 1/20 0.61
TRPM8 Q7Z2W7 7/20 0.53
PTPN11 Q06124 2/20 0.50
CDC7 O00311 9/20 0.49
DBF4 Q9UBU7 9/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2885122 0.92 MAPT (0.73) MAPTMEN1KMT2AKDM4EHSP90AA1
SCHEMBL2886264 0.86 TRPM8 (0.71) MAPTMEN1KMT2AKDM4EHSP90AA1
SCHEMBL13046766 0.86 CDC7 (0.67) MAPTMEN1KMT2AKDM4EHSP90AA1
SCHEMBL2883597 0.83 PTPN11 (0.69) MAPTMEN1KMT2AKDM4EHSP90AA1
SCHEMBL2886595 0.83 TRPM8 (0.71) MAPTMEN1KMT2AKDM4EHSP90AA1
SCHEMBL27717711 0.83 MAPT (0.70) MAPTMEN1KMT2AKDM4EHSP90AA1
SCHEMBL1316673 0.83 CDC7 (0.70) MAPTTRPM8PTPN11CDC7DBF4
SCHEMBL4484447 0.82 MAPT (0.76) MAPTMEN1KMT2AKDM4EHSP90AA1
SCHEMBL4804421 0.82 MAPT (0.76) MAPTMEN1KMT2AKDM4EHSP90AA1
SCHEMBL4467429 0.81 MAPT (0.74) MAPTMEN1KMT2AKDM4EHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7834030-B2 Phenyl-[1,2,4]-oxadiazol-5-one derivatives, pharmaceutical compositions and therapeutic use thereof SANOFI-AVENTIS (FR) 2010-11-16 US disclosed
US-7834030-B2 Phenyl-[1,2,4]-oxadiazol-5-one derivatives, pharmaceutical compositions and therapeutic use thereof SANOFI-AVENTIS (FR) 2010-11-16 US disclosed
US-20080262036-A1 Phenyl-[1,2,4]-oxadiazol-5-one Derivatives, Pharmaceutical Compositions and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 US disclosed
US-20080262036-A1 Phenyl-[1,2,4]-oxadiazol-5-one Derivatives, Pharmaceutical Compositions and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262036-A1 Phenyl-[1,2,4]-oxadiazol-5-one Derivatives, Pharmaceutical Compositions and Therapeutic Use Thereof GPR119, CPT1A, PC MAPT 1432/4885MEN1 3782/4885KMT2A 4613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.